Less may be more: breast cancer patients who respond fully could skip extra treatment
NCT ID NCT07407920
First seen Feb 20, 2026 · Last updated May 01, 2026 · Updated 6 times
Summary
This study looks at whether people with early HER2-positive or triple-negative breast cancer who had a complete response to initial treatment (no cancer found after surgery) and have no cancer DNA in their blood can safely receive less post-surgery therapy. The goal is to maintain the good outcome while reducing side effects. About 120 participants will be followed to see if this approach works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.